1 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow MAPRE1 protein, human: new trials by email Literature Review of MAPRE1 protein, human trials Research Report on MAPRE1 protein, human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer Atezolizumab + RP1 - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | Institut Curie | 2 | 2024-04-05 | 2025-06-11 |
| RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Vusolimogene oderparepvec (RP1) - Melanoma | Early Phase 1 | Recruiting | Yana Najjar | 25 | 2024-03-07 | 2026-04-13 |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies RP1, intra-tumoral injection, oncolytic virus - Merkel Cell Carcinoma, Basal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Replimune, Inc. | 69 | 2020-05-15 | 2026-04-22 |
Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Melanoma (1) · Neoplasms (1) · Skin Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Institut Curie (1) · Replimune, Inc. (1) · Yana Najjar (1)
United States (2) · France (1)
Jeannie Hou, MD (1) · Steven Le Gouill, PhD (1) · Yana Najjar, MD (1)